[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhangjiagang First People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100606801","phase-4-methylprednisolone-for-moderate-to-severe-traumatic-brain-injury-100606801",false,"NCT07180277","Methylprednisolone for Moderate to Severe Traumatic Brain Injury","A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Methylprednisolone Sodium Succinate Injection in Patients With Moderate to Severe Traumatic Brain Injury","ESM-TBI Trail","Inclusion Criteria:\n\n* Age 18-65 years.\n* Patients with moderate-to-severe traumatic brain injury whose Glasgow Coma Scale (GCS) score at admission is 4-12.\n* Study drug must be initiated within 12 hours after injury.\n* Imaging (CT) demonstrates cerebral contusion, or cerebral contusion with intracerebral hematoma.\n* Written informed consent obtained from the subject or legally authorised representative.\n\nExclusion Criteria:\n\n* Known hypersensitivity to corticosteroids or any contraindication to their use.\n* History of diabetes mellitus, or capillary blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL.\n* Shock at admission (systolic blood pressure \\\u003C90 mmHg for more than 30 minutes).\n* Pregnant or lactating women.\n* Participation in another clinical trial within the past 3 months.\n* Any condition that, in the investigator's opinion, renders the patient unsuitable for this study.","ALL","18 Years","65 Years",{"count":21,"type":22},520,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn if standard-dose methylprednisolone sodium succinate can improve neurological recovery and safety in adults with moderate to severe traumatic brain injury (TBI). The main questions it aims to answer are:\n\n1. Does adding a 5-day course of methylprednisolone improve overall long-term neurological outcome compared with placebo?\n2. Does methylprednisolone reduce 6-month mortality or increase the proportion of patients with good neurological recovery?\n3. What medical problems do participants experience when receiving methylprednisolone? Researchers will compare methylprednisolone sodium succinate (2 mg\u002Fkg\u002Fday intravenously for 5 days) with a matching placebo to see if the steroid improves outcomes beyond standard TBI care.\n\nParticipants will:\n\n1. Receive either methylprednisolone or placebo once daily for 5 days, added to guideline-directed standard care.\n2. Undergo CT scans and neuro-examinations during hospitalization.\n3. Return for follow-up visits at 1 month and 6 months after injury for neurological assessments, safety checks, and questionnaires.",[28],"Traumatic Brain Injury",[30,28],"Methylprednisolone","NOT_YET_RECRUITING","2025-09-17",{"date":34,"type":35},"2025-09-18","ACTUAL",{"date":37,"type":22},"2025-10-01",{"date":39,"type":22},"2028-03-01",{"name":41,"class":42},"Zhangjiagang First People's Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100575914","intradermal-acupuncture-and-self-rehabilitation-program-in-patients-with-severe-bells-palsy-100575914","NCT06778473","Intradermal Acupuncture and Self-rehabilitation Program in Patients With Severe Bell's Palsy","Effectiveness of Intradermal Acupuncture and Guided Self-rehabilitation Management Program for Severe Bell's Palsy Patients: a Randomized, Placebo-controlled, 2×2 Factorial Trial","Inclusion Criteria:\n\n* Patients diagnosed with Bell's palsy according to \"Clinical Practice Guideline: Bell's Palsy\" published by AAO-HNS in 2013;\n* First onset of Bell's palsy with only one side affected;\n* On the 10th day after the onset of palsy, HBGS score ranging from grade IV to VI;\n* According to the latest Chinese Guidelines for Bell's Palsy, within 72 hours of symptom onset for Bell's Palsy, oraling prednisolone 30mg qd for 5 days, followed by tapering to zero in decrements of 5 mg per day;\n* Adults aged 18 years of age or older (no limitation on gender).\n\nExclusion Criteria:\n\n* Facial paralysis caused by acoustic neuroma, otitis media, mastoiditis, mumps, Hunter's syndrome, cranial base meningitis, intracranial metastasis of cancer or multiple sclerosis;\n* Fear of intradermal acupuncture;\n* allergy to adhesive tape;\n* Severe allergic diseases, significant skin lesions, tumors, and severe or unstable internal diseases involving the cardiovascular, respiratory, endocrine, digestive, or hematological system;\n* Cognitive impairment, mental illness, contagious disease, pregnant and lactating;\n* Previously treated withintradermal acupuncture or participating in other clinical trial within 3 months.",{"count":51,"type":22},552,[53],"NA","This study aims to assess the effect of intradermal acupuncture(IA) and guided self-rehabilitation management program(GRMP) (either single or combined) for patients with severe Bell's Palsy.",[56],"Bell Palsy",[56,58,59],"Intradermal acupuncture","Self-rehabilitation","RECRUITING","2025-04-27",{"date":63,"type":35},"2025-04-30",{"date":65,"type":35},"2025-03-24",{"date":67,"type":22},"2029-12-31",{"name":41,"class":42},1,""]